RETA - Reata Pharmaceuticals, Inc.
| Previous Close | 60.78 |
| Open | 61.00 |
| Bid | 51.00 x 1100 |
| Ask | 64.00 x 1200 |
| Day's Range | 58.37 - 61.31 |
| 52 Week Range | 19.31 - 99.50 |
| Volume | 150,724 |
| Avg. Volume | 454,500 |
| Market Cap | 1.746B |
| Beta (3Y Monthly) | 2.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.06 |
| Earnings Date | Aug 9, 2017 - Aug 14, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 131.57 |
- GlobeNewswire•7 days ago
Reata Announces Presentation of Four Clinical Abstracts at the American Society of Nephrology Kidney Week 2018
IRVING, Texas, Oct. 16, 2018 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that four abstracts highlighting Reata’s.
- GlobeNewswire•14 days ago
Research Report Identifies Cerner, Reata Pharmaceuticals, Lennar, Acacia Communications, GoPro, and ProAssurance with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•28 days ago
Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in IgA Nephropathy and Type 1 Diabetic Chronic Kidney Disease
Statistically Significant Improvement in Kidney Function Observed in Both Diseases After 12 Weeks of Treatment Conference Call with Management Scheduled for Today at 8:00 am ET.
- Zacks•last month
Is the Options Market Predicting a Spike in Reata Pharmaceuticals (RETA) Stock?
Investors need to pay close attention to Reata Pharmaceuticals (RETA) stock based on the movements in the options market lately.
- Simply Wall St.•last month
Who Just Ramped Up Their Shares In Reata Pharmaceuticals Inc (NASDAQ:RETA)?
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellularRead More...
Market Realist•last monthReata Pharmaceuticals: One of Best-Performing Biotech Stocks YTD
These Biotech Stocks Have Returned More Than 100% Year-to-DateGrowth trends for Reata Pharmaceuticals
- GlobeNewswire•2 months ago
Reata Announces Receipt of $30 Million Milestone Payment From Kyowa Hakko Kirin
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that it has received a $30 million milestone payment from its licensee, Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), following the initiation of AYAME, a Phase 3 clinical trial to assess the efficacy and safety of bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease in Japan. In December 2009, Reata granted Kyowa Hakko Kirin the exclusive license to develop and commercialize bardoxolone in renal disease and certain other indications in Japan, China, Taiwan, South Korea, and Southeast Asia.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of RETA earnings conference call or presentation 8-Aug-18 8:30pm GMT
Q2 2018 Reata Pharmaceuticals Inc Earnings Call
- Zacks•2 months ago
Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -40.54% and -16.89%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•2 months ago
Reata Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results and an Update on Development Programs
IRVING, Texas, Aug. 08, 2018-- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today provided an update on the Company's product development programs and announced financial results ...
- GlobeNewswire•3 months ago
Reata Pharmaceuticals, Inc. to Report Second Quarter 2018 Financial Results and an Update on Development Programs on Wednesday, August 8, 2018
IRVING, Texas, Aug. 06, 2018-- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and live webcast on Wednesday, August ...
- Motley Fool•3 months ago
3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys?
These stocks jumped much higher over the last few days. But should investors jump on the bandwagon?
- GlobeNewswire•3 months ago
Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 3,450,000 shares of its Class A common stock, which included 450,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $72.00 per share. The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $248.4 million. Reata intends to use the net proceeds from the offering for working capital and general corporate purposes, which include, but are not limited to, advancing the development of bardoxolone methyl and omaveloxolone through clinical trials, preparing to file one or more New Drug Applications, and planning for commercialization of its potential products.
- GlobeNewswire•3 months ago
Investor Expectations to Drive Momentum within Reata Pharmaceuticals, Shoe Carnival, United Fire Group, Approach Resources, Saul Centers, and Tennant — Discovering Underlying Factors of Influence
NEW YORK, July 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Reata ...
- ACCESSWIRE•3 months ago
These Biotech Stocks Should Be On Your Watch-List
CORAL GABLES, FL / ACCESSWIRE / July 24, 2018 / The Nasdaq Biotechnology Index (IBB) just made a new 52-week high today and most likely an all-time high may not be out of the question either. As most of the market shutters about the trade wars, biotech stocks are more insulated from the biggest concern about tariffs compared to most industries. Biotech companies like GT Biopharma, Inc. (GTBP), Reata Pharmaceuticals (NASDAQ: RETA) and Biogen (NASDAQ: BIIB) have all released news within the last 10 days that has sparked much more interest in the market for these stocks.
- ACCESSWIRE•3 months ago
Today’s Research Reports on Stocks to Watch: Reata Pharmaceuticals and LifePoint Health
NEW YORK, NY / ACCESSWIRE / July 24, 2018 / Both Reata Pharmaceuticals and LifePoint were trading significantly higher on strong trading volume after Wall Street learned about positive developments from ...
- Motley Fool•3 months ago
Here's Why Reata Pharmaceuticals Skyrocketed 65% Today
A drug targeting a rare form of chronic kidney disease is fueling investor's optimism.
Market Realist•3 months agoWhy Reata Pharmaceuticals’ Stock Price Is Skyrocketing Today
Today, Reata Pharmaceuticals is trading at a stock price of $75.00, which represents a ~61.67% hike from yesterday’s close of $46.4. On July 20, Reata Pharmaceuticals closed at $46.4, which represents ~140% growth from its 52-week low of $19.31 on March 29. Also today, Reata Pharmaceuticals hit a 52-week high of $76.25.
- Zacks•3 months ago
Can The Uptrend Continue for Reata Pharmaceuticals (RETA)?
Investors certainly have to be happy with Reata Pharmaceuticals, Inc. (RETA) and its short term performance.
